REPLIGEN CORP

RGEN

REPLIGEN CORP

RGEN

Insider Sentiment (TTM):

Last Purchase:2025-08-08Last Sale:2026-06-25Shares Purchased (TTM):0Shares Sold (TTM):88,183

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:57,914,905Shares Outstanding:56,354,000Institutional Ownership Pct.:102.77%

Earnings Market Reaction:

Filing Date:2026-07-29Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	607	583	566	749	709	697	757	784	809	781	751	631
Held To Maturity Securities Current	-	-	-	-	-	-	-	-	-	-	0	0
Marketable Securities Current	204	202	202	-	-	-	0	-	-	-	-	-
Accounts Receivable Net Current	158	152	159	149	157	147	134	129	123	116	124	106
Inventory Net	187	179	170	160	156	153	143	182	191	198	202	211
Assets Of Disposal Group Including Discontinued Op…	-	-	-	-	-	-	-	-	1	1	-	-
Prepaid Expense And Other Assets Current	46	46	41	38	35	35	32	36	33	36	34	32
Assets Current	1,201	1,161	1,137	1,096	1,057	1,032	1,066	1,132	1,157	1,131	1,111	980
Property Plant And Equipment Net	168	173	187	189	193	196	198	203	205	206	207	202
Intangible Assets Net Excluding Goodwill	358	368	386	395	406	409	398	381	386	394	407	350
Goodwill	1,104	1,107	1,114	1,113	1,114	1,082	1,031	988	986	986	987	869
Deferred Income Tax Assets Net	1	1	1	1	1	1	1	0	1	1	2	2
Operating Lease Right Of Use Asset	116	114	120	124	128	130	135	127	131	135	116	118
Other Assets Noncurrent	4	6	5	5	3	2	1	1	1	1	1	1
Assets Noncurrent	-	-	1,812	1,827	1,845	1,820	1,764	1,699	1,709	1,723	1,720	1,542
Assets	2,950	2,931	2,950	2,924	2,902	2,852	2,830	2,831	2,866	2,854	2,831	2,523
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	33	35	30	29	26	27	32	21	21	19	20	19
Operating Lease Liability Current	19	21	22	19	16	15	15	12	12	10	6	3
Business Combination Contingent Consideration Liab…	3	5	5	5	5	34	17	14	14	24	13	13
Convertible Notes Payable Current	-	-	-	-	-	-	0	0	69	69	69	286
Accrued Liabilities Current	77	65	79	77	76	76	62	61	58	59	57	58
Liabilities Current	133	126	136	131	123	152	127	108	175	182	165	379
Convertible Debt Noncurrent	-	-	-	-	534	530	526	522	518	514	510	-
Long Term Debt	551	547	542	538	-	-	526	-	-	-	-	-
Deferred Tax And Other Liabilities Noncurrent	17	15	22	20	23	24	23	34	34	37	39	15
Operating Lease Liability Noncurrent	121	120	126	132	136	139	146	139	144	145	127	131
Business Combination Contingent Consideration Liab…	0	1	1	2	7	5	20	0	0	0	14	14
Other Liabilities Noncurrent	17	17	16	17	17	17	17	12	11	11	11	11
Liabilities Noncurrent	-	-	708	709	717	715	730	706	707	707	701	170
Liabilities	838	825	844	841	840	867	857	814	882	888	866	549
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	1	1	1	1	1	1	1	1	1	1	1	1
Additional Paid In Capital Common Stock	1,662	1,655	1,652	1,644	1,635	1,620	1,617	1,610	1,586	1,572	1,569	1,567
Accumulated Other Comprehensive Income Loss Net Of…	-20	-14	-3	-4	-2	-48	-53	-35	-44	-43	-38	-43
Retained Earnings Accumulated Deficit	470	465	456	443	428	413	407	441	442	436	433	449
Stockholders Equity	2,112	2,105	2,106	2,083	2,062	1,985	1,973	2,017	1,984	1,966	1,965	1,974
Liabilities And Stockholders Equity	2,950	2,931	2,950	2,924	2,902	2,852	2,830	2,831	2,866	2,854	2,831	2,523
Allowance For Doubtful Accounts Receivable Current	3	3	3	2	2	2	2	2	2	2	2	2
Preferred Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Common Stock Shares Authorized	80	80	80	80	80	80	80	80	80	80	80	80
Common Stock Shares Issued	56	56	56	56	56	56	56	56	56	56	56	56
Shares Outstanding	56	56	56	56	56	56	56	56	56	56	56	56

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-1.44%	16.90%	4.93%	-	-	-	-	-	-	-	-	-
2025	-15.26%	-14.76%	-16.62%	7.75%	10.65%	46.52%	16.40%	13.12%	10.48%	-14.79%	-1.83%	-23.03%
2024	-0.13%	-20.86%	-21.82%	-8.59%	-10.97%	-8.49%	26.74%	25.48%	26.45%	-25.68%	-6.05%	-21.61%
2023	-	-	-	-3.35%	-5.82%	-14.38%	20.23%	35.79%	32.30%	-1.79%	-11.31%	-13.75%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	9.05	9.20	8.37	8.36	8.59	6.79	8.41	10.44	6.62	6.23	6.74	2.59
Quick Ratio	7.30	7.42	6.82	6.85	7.04	5.56	7.03	8.43	5.34	4.94	5.31	1.94
Working Capital	1.07B	1.04B	1.00B	965.35M	933.85M	880.47M	939.25M	1.02B	981.96M	949.54M	946.40M	601.53M
Leverage & Debt
Debt to Equity	0.40	0.39	0.40	0.40	0.41	0.44	0.43	0.40	0.44	0.45	0.44	0.28
Interest Coverage TTM	2.92	2.95	2.56	0.04	-1.13	-2.03	-2.26	0.96	3.57	5.71	24.33	77.94
Debt Ratio	0.28	0.28	0.29	0.29	0.29	0.30	0.30	0.29	0.31	0.31	0.31	0.22
Efficiency & Turnover
Asset Turnover TTM	0.27	0.26	0.26	0.25	0.23	0.23	0.22	0.24	0.23	0.23	0.24	0.26
Days Sales Outstanding TTM	73.14	71.48	72.36	71.67	75.87	73.84	74.29	67.75	71.71	73.35	69.38	62.60
Receivables Turnover TTM	4.99	5.11	5.04	5.09	4.81	4.94	4.91	5.39	5.09	4.98	5.26	5.83
Per Share Metrics
Diluted EPS TTM	0.73	0.91	0.86	0.03	-0.24	-0.41	-0.46	-0.14	0.17	0.42	0.63	1.77
Free Cash Flow Per Share TTM	1.98	1.88	1.67	1.95	1.94	2.22	2.68	2.39	2.19	2.00	1.39	1.81
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	53.52%	52.82%	52.32%	45.73%	44.62%	44.47%	43.29%	49.61%	44.10%	43.81%	44.03%	45.37%
Operating Profit Margin TTM	8.23%	8.45%	7.47%	0.11%	-3.54%	-4.96%	-5.53%	1.78%	3.84%	6.06%	7.54%	13.28%
Net Profit Margin TTM	5.29%	6.73%	6.62%	0.25%	-2.05%	-3.53%	-4.02%	-1.28%	1.53%	3.80%	5.63%	15.44%
Growth Metrics
Net Revenue Growth (1Y)	16.49%	17.36%	16.36%	11.74%	8.73%	4.88%	0.33%	-2.91%	-12.95%	-18.45%	-21.11%	-18.57%
Net Income Growth (1Y)	-400.42%	-323.66%	-291.64%	-121.47%	-245.82%	-197.56%	-171.68%	-108.03%	-92.37%	-84.74%	-80.86%	-39.42%
EPS Growth (1Y)	-399.44%	-322.74%	-290.62%	-121.37%	-244.92%	-196.98%	-171.40%	-108.00%	-92.39%	-84.79%	-80.95%	-39.71%
Valuation Metrics
P/E TTM	185.31	129.18	188.46	4,327.35	-505.85	-310.75	-315.57	-1,029.74	742.96	435.62	281.45	87.99
P/B TTM	3.64	3.15	4.38	3.61	3.39	3.60	4.08	4.13	3.55	5.22	5.10	4.49
P/S TTM	9.80	8.70	12.48	10.62	10.38	10.98	12.69	13.16	11.37	16.55	15.84	13.59
Market Cap	7.70B	6.64B	9.21B	7.52B	6.99B	7.14B	8.05B	8.34B	7.04B	10.26B	10.02B	8.87B
Enterprise Value	7.64B	6.60B	9.19B	7.31B	6.82B	6.97B	7.82B	8.07B	6.82B	10.06B	9.85B	8.52B
Calculated Values
Free Cash Flow TTM	111.97M	106.04M	93.90M	109.98M	108.92M	124.80M	149.72M	134.06M	122.57M	111.41M	77.70M	101.16M
Net Debt	-57.76M	-38.06M	-23.81M	-210.82M	-175.13M	-167.62M	-231.79M	-262.36M	-221.94M	-197.22M	-171.73M	-344.82M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-25Sale

Owner: Garland, Jason K

Title: CFO

Shares: 733

Price/Share: $145.00

Value: $106,285.00

Shares Owned: 19,359

Relationship: Officer

Ownership: Direct

2026-04-21Sale

Owner: Loeillot, Olivier

Title: Chief Executive Officer

Shares: 3,832

Price/Share: $140.00

Value: $536,480.00

Shares Owned: 54,246

Relationship: Director,Officer

Ownership: Direct

2025-12-17Sale

Owner: Dawes, Karen A

Title: -

Shares: 275

Price/Share: $161.00

Value: $44,275.00

Shares Owned: 91,821

Relationship: Director

Ownership: Direct

2025-11-25Sale

Owner: Loeillot, Olivier

Title: Chief Executive Officer

Shares: 7,041

Price/Share: $170.00

Value: $1,196,970.00

Shares Owned: 35,898

Relationship: Director,Officer

Ownership: Direct

2025-11-18Sale

Owner: Bylund, James

Title: Chief Operating Officer

Shares: 2,191

Price/Share: $151.21

Value: $331,301.11

Shares Owned: 21,520

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-25	Garland, Jason K	Officer	CFO	Direct	Sale	733	145.00	$106,285.00	19,359	4
2026-04-21	Loeillot, Olivier	Director,Officer	Chief Executive Officer	Direct	Sale	3,832	140.00	$536,480.00	54,246	4
2025-12-17	Dawes, Karen A	Director	-	Direct	Sale	275	161.00	$44,275.00	91,821	4
2025-11-25	Loeillot, Olivier	Director,Officer	Chief Executive Officer	Direct	Sale	7,041	170.00	$1,196,970.00	35,898	4
2025-11-18	Bylund, James	Officer	Chief Operating Officer	Direct	Sale	2,191	151.21	$331,301.11	21,520	4
2025-11-13	Hunt, Anthony	Director	-	Direct	Sale	20,000	154.20	$3,084,000.00	80,743	4
2025-11-12	Hunt, Anthony	Director	-	Direct	Sale	25,000	156.79	$3,919,750.00	100,743	4
2025-09-10	Hunt, Anthony	Director	-	Direct	Sale	29,111	119.69	$3,484,295.59	100,743	4
2025-08-08	Madaus, Martin D	Director	-	Indirect	Purchase	1,800	112.13	$201,834.00	1,800	4
2025-05-15	Hunt, Anthony	Director	-	Direct	Sale	26,447	124.55	$3,293,973.85	109,854	4
2025-03-17	Hunt, Anthony	Director	-	Direct	Sale	26,756	151.33	$4,048,985.48	136,301	4
2025-03-17	Pax, Margaret	Director	-	Direct	Purchase	250	150.69	$37,672.50	1,043	4
2024-11-21	Hunt, Anthony	Director	-	Direct	Sale	24,246	139.67	$3,386,438.82	139,840	4
2024-09-10	Hunt, Anthony	Director	-	Direct	Sale	22,191	145.32	$3,224,796.12	139,840	4
2024-08-02	Kuriyel, Ralf	Officer	Senior VP, R&D	Direct	Sale	7,148	159.11	$1,137,318.28	12,288	4
2024-08-01	Kuriyel, Ralf	Officer	Senior VP, R&D	Direct	Sale	4,465	165.67	$739,716.55	19,261	4
2024-06-14	Barthelemy, Nicolas	Director	-	Direct	Purchase	1,200	125.45	$150,540.00	4,668	4
2024-06-14	Hunt, Anthony	Officer	Chief Executive Officer	Direct	Purchase	2,000	124.08	$248,160.00	165,177	4
2024-06-14	Madaus, Martin D	Director	-	Direct	Purchase	1,615	125.00	$201,875.00	4,613	4
2024-05-21	Hunt, Anthony	Officer	Chief Executive Officer	Direct	Sale	20,072	168.68	$3,385,744.96	163,177	4
2024-03-11	Kuriyel, Ralf	Officer	Senior VP, R&D	Direct	Sale	3,517	193.73	$681,348.41	24,260	4
2024-03-08	Hunt, Anthony	Officer	Chief Executive Officer	Direct	Sale	16,707	199.02	$3,325,027.14	185,249	4
2024-02-27	Dawes, Karen A	Director	-	Direct	Sale	1,000	193.35	$193,350.00	87,367	4
2024-02-23	Bylund, James	Officer	Chief Operating Officer	Direct	Sale	4,373	198.08	$866,203.84	14,135	4
2023-11-10	Gebski, Christine	Officer	See Remarks	Direct	Sale	3,788	147.13	$557,328.44	28,787	4
2023-08-29	Dawes, Karen A	Director	-	Direct	Sale	850	171.38	$145,673.00	83,741	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

102.77%

Inst. Shares: 57,914,905

Shares Outstanding: 56,354,000

2025-12-31

99.38%

Inst. Shares: 55,886,023

Shares Outstanding: 56,234,000

2025-09-30

96.32%

Inst. Shares: 54,197,127

Shares Outstanding: 56,265,000

2025-06-30

85.68%

Inst. Shares: 48,180,339

Shares Outstanding: 56,234,000

2025-03-31

83.72%

Inst. Shares: 46,985,372

Shares Outstanding: 56,123,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	57,914,905	56,354,000	102.77%
2025-12-31	55,886,023	56,234,000	99.38%
2025-09-30	54,197,127	56,265,000	96.32%
2025-06-30	48,180,339	56,234,000	85.68%
2025-03-31	46,985,372	56,123,000	83.72%
2024-12-31	46,292,884	55,937,000	82.76%
2024-09-30	46,539,720	56,012,000	83.09%
2024-06-30	48,531,797	55,884,000	86.84%
2024-03-31	49,803,146	55,791,000	89.27%
2023-12-31	51,284,790	55,720,000	92.04%
2023-09-30	50,273,051	55,766,000	90.15%
2023-06-30	48,048,294	55,705,000	86.25%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

REPLIGEN CORP (RGEN) — SEC Financial Statements & Analysis

REPLIGEN CORP (RGEN) is a biological products, (no diagnostic substances) company, incorporated in DE. REPLIGEN CORP trades on Nasdaq as: RGEN. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), REPLIGEN CORP reported a 16.49% year-over-year revenue growth, a Gross Profit Margin of 53.52% (TTM), a Debt-to-Equity ratio of 0.40x, a Price-to-Sales (P/S) ratio of 9.80x (TTM), a Price-to-Book (P/B) ratio of 3.64x (TTM), at a market cap of $7.70B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 16.49%
Gross Profit Margin TTM: 53.52%
Debt To Equity: 0.40x
P/S TTM: 9.80x
P/B TTM: 3.64x
Market Cap: $7.70B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is REPLIGEN CORP in?

REPLIGEN CORP (RGEN) operates in the Biological Products, (No Diagnostic Substances) industry.

What is RGEN's market cap?

REPLIGEN CORP (RGEN) has a market capitalization of $7.70B as of 2026-06-30.

What is RGEN's P/E ratio?

REPLIGEN CORP (RGEN)'s trailing twelve month P/E ratio is 185.31x as of 2026-06-30.

What exchange does RGEN trade on?

REPLIGEN CORP (RGEN) trades on the Nasdaq.

Where is REPLIGEN CORP incorporated?

REPLIGEN CORP is incorporated in DE.

REPLIGEN CORP

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

REPLIGEN CORP (RGEN) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Biological Products, (No Diagnostic Substances)

Wall Street's data.
Main Street's price.

REPLIGEN CORP (RGEN) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Biological Products, (No Diagnostic Substances)

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.